A Stability-Indicating Ultra-Performance Liquid Chromatographic Method for Estimation of Related Substances and Degradants in Paliperidone Active Pharmaceutical Ingredient and its Pharmaceutical Dosage Forms
Authors:
Open Access
- 9 March 2012
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Chromatographic Science
- Vol. 50 (4) , 368-372
Abstract
A simple, linear gradient, rapid, precise and stability-indicating analytical method was developed for the estimation of related substances and degradants of paliperidone API and tablets. The chromatographic separations were achieved using an Acquity ultra-performance liquid chromatograph (BEH 100 mm, 2.1 mm, 1.7 µm C-18 column) employing 0.01 M potassium dihydrogen phosphate buffer (pH 2.0) as mobile phase A and acetonitrile–water (9:1) as mobile phase B. A linear gradient (mobile phase A, mobile phase B in the ratio of 84:16) with a 0.45 mL/min flow rate was chosen. All six impurities were eluted within five minutes of run time. The column temperature was maintained at 25°C and a detector wavelength of 238 nm was employed. Paliperidone was exposed to thermal, photolytic, hydrolytic and oxidative stress conditions. The stressed samples were analyzed by the proposed method. Considerable degradation of the analyte was observed when it was subjected to oxidative conditions and impurity F was found to be the major degradant. Peak homogeneity data of paliperidone obtained by photodiode array (PDA) detection demonstrated the specificity of the method in the presence of degradants. The method was validated with respect to linearity, precision, accuracy, ruggedness, robustness, limit of detection and limit of quantification.Keywords
This publication has 11 references indexed in Scilit:
- Simultaneous determination of risperidone and 9-hydroxyrisperidone enantiomers in human blood plasma by liquid chromatography with electrochemical detectionJournal of Pharmaceutical and Biomedical Analysis, 2009
- Determination of risperidone and 9‐Hydroxyrisperidone using HPLC, in plasma of children and adolescents with emotional and behavioural disordersBiomedical Chromatography, 2009
- Validated LC–MS/MS methods for the determination of risperidone and the enantiomers of 9-hydroxyrisperidone in human plasma and urineJournal of Chromatography B, 2008
- LC with Column-Switching and Spectrophotometric Detection for Determination of Risperidone and 9-Hydroxyrisperidone in Human SerumChromatographia, 2008
- Treatment of schizophrenia with paliperidone extended-release tablets: A 6-week placebo-controlled trial☆Schizophrenia Research, 2007
- Risperidone and Paliperidone Inhibit P-Glycoprotein Activity In VitroNeuropsychopharmacology, 2006
- UPLC™: An Introduction and ReviewJournal of Liquid Chromatography & Related Technologies, 2005
- Determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography: application to the evaluation of CYP2D6 drug interactionsJournal of Chromatography B, 2003
- Determination of risperidone and 9-hydroxyrisperidone in human plasma by high-performance liquid chromatography: application to therapeutic drug monitoring in Japanese patients with schizophreniaJournal of Pharmaceutical and Biomedical Analysis, 1999
- Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4Naunyn-Schmiedeberg's Archives of Pharmacology, 1999